Goldman Sachs Turns Bearish on MoonLake
Goldman Sachs downgraded MoonLake Immunotherapeutics to Sell, citing high approval risks despite progress in Phase 3 trials.
/ 1661 items
#XY↓
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Biogen Reports $222M R&D Charge Impact on Q4 2025 Earnings
Biogen discloses $222 million charge for research partnerships and licensing agreements, reducing Q4 2025 earnings by $1.26 per share in SEC filing.
Glaukos Stock Drops on Slower iDose Growth Despite Strong Q4 Results
Glaukos shares fell 9% after Q4 iDose sales growth disappointed investors, though the company maintained its 2026 revenue guidance of $600-620 million.
TG Therapeutics Stock Rises on Strong Briumvi Sales and Raised Guidance
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.
FDA Extends Review Timeline for Travere's FSGS Treatment
FDA delays approval decision for Filspari in rare kidney disease FSGS until April 2026. Travere Therapeutics (TVTX) continues commercial preparations for potential first FSGS treatment.